Пиклиденосон (Piclidenoson; CF101)
Международное непатентованное наименование
Пиклиденосон (Piclidenoson; CF101)
Торговое наименование
Piclidenoson
Производитель, страна
Can-Fite BioPharma, Israel
Механизм действия
Piclidenoson is an A3 adenosine receptor agonist which ultimately de-regulates the Wnt/β-catenin pathway and inhibits inflammatory cytokine production. Since a major part of the pathophysiology of severe COVID-19 involves an overproduction of inflammatory cytokines, this therapeutic drug may mitigate this aspect of the disease.
Публикации COVID-19
, , et al. Augmented Curation of Unstructured Clinical Notes from a Massive EHR System Reveals Specific Phenotypic Signature of Impending COVID-19 Diagnosis. DOI: 10.1101/2020.04.19.20067660.
Cohen S, Fishman P. Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy. Drug Des Devel Ther. 2019 Jan 30;13:491-497. DOI: 10.2147/DDDT.S195294.
Клинические исследования
1.
Название протокола
Piclidenoson for Treatment of COVID-19 - A Randomized Open Label Pilot Trial
Дата начала и окончания КИ
April 6, 2020 - July 6, 2020
Название организации, проводящей КИ
Can-Fite BioPharma
Страны
Israel
Фаза
II
Кол-во пациентов
40